Business of Regenerative Medicine: Defining and Creating Value
We will explore how advances in cell and gene therapy, drug development, and bioengineerng in regenerative medicine are moving from the lab to the patient - and what it will take to identify real, lasting value for business and society.
Breakthrough technologies are thrilling in their novelty and can be transformative in their application, but regenerative medicine technologies defy the normal paradigms of both business model development and market-potential assessment.
How does one ‘define value’ when considering such a new technology? How does one ‘create value’ when building a company on a novel platform? In today’s market, how does one price such an innovation in different healthcare systems?
At the 12th annual Business of Regenerative Medicine: Defining and Creating Value, you will engage with CEOs, venture capitalists, experts in biomedical research, and patient advocates to make sense of this complex and shifting landscape.